1. Preclinical to clinical translation of cenerimod, a novel S1P 1 receptor modulator, in systemic lupus erythematosus.
- Author
-
Strasser DS, Froidevaux S, Sippel V, Gerossier E, Grieder U, Pierlot GM, Kieninger-Graefitsch A, Vezzali E, Stalder AK, Renault B, Ryge J, Hart A, Mentzel U, Groenen PMA, Keller MP, Trendelenburg M, Martinic MM, and Murphy MJ
- Subjects
- Animals, Biomarkers, Cellular Microenvironment drug effects, Cellular Microenvironment genetics, Cellular Microenvironment immunology, Disease Models, Animal, Dose-Response Relationship, Drug, Drug Evaluation, Preclinical methods, Humans, Lupus Erythematosus, Systemic drug therapy, Lupus Erythematosus, Systemic etiology, Lupus Erythematosus, Systemic pathology, Lymphocytes drug effects, Lymphocytes immunology, Lymphocytes metabolism, Mice, Mice, Inbred MRL lpr, Molecular Targeted Therapy, Plasma Cells drug effects, Plasma Cells immunology, Plasma Cells metabolism, Translational Research, Biomedical, Lupus Erythematosus, Systemic metabolism, Oxadiazoles pharmacology, Propylene Glycols pharmacology, Sphingosine-1-Phosphate Receptors metabolism
- Abstract
Competing Interests: Competing interests: DSS, SF, VS, EG, UG, GP, EV, AKS, BR, JR, AH, UM, PMAG, MPK, MMM, and MJM are employees of Idorsia Pharmaceuticals Ltd. MT, grant research support.
- Published
- 2020
- Full Text
- View/download PDF